Cargando…

Recent Advances in Zirconium-89 Chelator Development

The interest in zirconium-89 ((89)Zr) as a positron-emitting radionuclide has grown considerably over the last decade due to its standardized production, long half-life of 78.2 h, favorable decay characteristics for positron emission tomography (PET) imaging and its successful use in a variety of cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatt, Nikunj B., Pandya, Darpan N., Wadas, Thaddeus J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017441/ https://www.ncbi.nlm.nih.gov/pubmed/29534538 http://dx.doi.org/10.3390/molecules23030638

Ejemplares similares

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice
por: N.Tinianow, Jeff, et al.
Publicado: (2016)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2015)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography
por: Pandya, Darpan N., et al.
Publicado: (2020)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability
por: Kang, Chi Soo, et al.
Publicado: (2022)

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Development of Targeted Alpha Particle Therapy for Solid Tumors
por: Tafreshi, Narges K., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
por: Pandya, Darpan N., et al.
Publicado: (2016)

IL13RA2 targeted alpha particle therapy against glioblastomas
por: Sattiraju, Anirudh, et al.
Publicado: (2017)

Synthesis and Biomedical Applications of Zirconium Nanoparticles: Advanced Leaps and Bounds in the Recent Past
por: Arshad, Hafiz Muhammad, et al.
Publicado: (2022)

Recent Advances in π-Conjugated N^C-Chelate Organoboron Materials
por: Haque, Ashanul, et al.
Publicado: (2020)

A new technique for the radiolabelling of mixed leukocytes with zirconium‐89 for inflammation imaging with positron emission tomography
por: Fairclough, M., et al.
Publicado: (2016)

Recent Advances in Iron Chelation and Gallium-Based Therapies for Antibiotic Resistant Bacterial Infections
por: Vinuesa, Víctor, et al.
Publicado: (2021)

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach
por: Even, Aniek J.G., et al.
Publicado: (2016)

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe
por: Ahmed, Mona, et al.
Publicado: (2020)

Zirconium Coordination Chemistry and Its Role in Optimizing Hydroxymate Chelation: Insights from Molecular Dynamics
por: Sormani, Giulia, et al.
Publicado: (2023)

Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential
por: Wuensche, Thomas E., et al.
Publicado: (2022)

Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases
por: Patel, Chirayu M., et al.
Publicado: (2021)

Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies
por: Abou, Diane S., et al.
Publicado: (2022)

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments
por: Sales, Thais A., et al.
Publicado: (2019)

Advances on Chelation and Chelator Metal Complexes in Medicine †
por: Kontoghiorghes, George J.
Publicado: (2020)

Labour analgesia: Recent advances
por: Pandya, Sunil T
Publicado: (2010)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Novel Bifunctional Cyclic Chelator for (89)Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates
por: Zhai, Chuangyan, et al.
Publicado: (2015)

Engineering Intrinsically Zirconium‐89 Radiolabeled Self‐Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies
por: Goel, Shreya, et al.
Publicado: (2016)

On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study
por: Lacerda, Sara, et al.
Publicado: (2022)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_emt2kq6uqe32ccu3uclo3u9osg